Journal article
TNF-a+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies
Cell reports. Medicine, Vol.3(6), 100640
06/21/2022
DOI: 10.1016/j.xcrm.2022.100640
PMID: 35588734
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific CD4(+) T cells are likely important in immunity against coronavirus 2019 (COVID-19), but our understanding of CD4(+) longitudinal dynamics following infection and of specific features that correlate with the maintenance of neutralizing antibodies remains limited. Here, we characterize SARS-CoV-2-specific CD4(+)T cells in a longitudinal cohort of 109 COVID19 outpatients enrolled during acute infection. The quality of the SARS-CoV-2-specific CD4(+) response shifts from cells producing interferon gamma (IFN gamma) to tumor necrosis factor alpha (TNF-alpha) from 5 days to 4 months post-enrollment, with IFN gamma-IL-21-TNF-alpha(+) CD4(+) T cells the predominant population detected at later time points. Greater percentages of IFN gamma-IL-21-TNF-alpha(+) CD4(+)T cells on day 28 correlate with SARS-CoV-2-neutralizing antibodies measured 7 months post-infection (? = 0.4, p = 0.01). mRNA vaccination following SARS-CoV-2 infection boosts both IFN gamma- and TNF-alpha-producing, spike-protein-specific CD4(+) T cells. These data suggest that SARS-CoV-2-specific, TNF-alpha-producing CD4(+) T cells may play an important role in antibody maintenance following COVID-19.
Details
- Title: Subtitle
- TNF-a+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies
- Creators
- Kattria van der Ploeg - Stanford MedicineAdam S. Kirosingh - Stanford UniversityDiego A. M. Mori - Stanford MedicineSaborni Chakraborty - Stanford MedicineZicheng Hu - University of California, San FranciscoBenjamin L. Sievers - J. Craig Venter InstituteKaren B. Jacobson - Stanford MedicineHector Bonilla - Stanford MedicineJulie Parsonnet - Stanford MedicineJason R. Andrews - Stanford MedicineKathleen D. Press - Stanford MedicineMaureen C. Ty - Stanford MedicineDaniel R. Ruiz-Betancourt - Stanford MedicineLauren de la Parte - Stanford MedicineGene S. Tan - University of California San DiegoCatherine A. Blish - Chan Zuckerberg Biohub San FranciscoSaki Takahashi - University of California, San FranciscoIsabel Rodriguez-Barraquer - University of California, San FranciscoBryan Greenhouse - University of California, San FranciscoUpinder Singh - Stanford MedicineTaia T. Wang - Stanford UniversityPrasanna Jagannathan - Stanford Medicine
- Resource Type
- Journal article
- Publication Details
- Cell reports. Medicine, Vol.3(6), 100640
- DOI
- 10.1016/j.xcrm.2022.100640
- PMID
- 35588734
- NLM abbreviation
- Cell Rep Med
- ISSN
- 2666-3791
- eISSN
- 2666-3791
- Publisher
- Elsevier
- Number of pages
- 21
- Grant note
- T32AI052073; K24AI144048; U01AI150741 / National Institute of Allergy and Infectious Diseases; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) U01 AI150741-01S1 / NIH/NIAID Fastgrant Stanford's Innovative Medicines Accelerator Eiger BioPharmaceuticals Stanford School of Medicine Research Office National Center for Research Resources UL1TR003142 / National Center for Advancing Translational Sciences; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS) UL1 TR001085 / National Center for Advancing Translational Sciences, National Institutes of Health
- Language
- English
- Date published
- 06/21/2022
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985244663102771
Metrics
1 Record Views